Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsOscar Health ESA Exceptions Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentOscar HealthPolicy CG084

    Erythropoiesis-Stimulating Agent (ESA) - Medical Benefit Preferred Physician-Administered Drug Exceptions Criteria

    Customize your policy alerts

    Sign up for Oscar Health Policy CG084 alerts

    Get alerted when Policy CG084 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization exceptions for non-preferred, physician-administered erythropoiesis-stimulating agents under the medical benefit when preferred products cannot be used, subject to clinical documentation, medical necessity, applicable law, and member benefit terms.

    Policy Summary
    PayerOscar Health
    PolicyErythropoiesis-Stimulating Agent (ESA) - Medical Benefit Preferred Physician-Administered Drug Exceptions Criteria
    Policy CodePolicy CG084
    Change TypeNo material change
    Effective DateApr 1, 2026
    Last ReviewDec 2, 2024
    Next Review DateN/A
    Key ActionSubmit prior authorization with clinical documentation supporting the non-preferred ESA exception.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    3preferred ESA products
    2

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    non-preferred ESA products
    6exception pathways
    12 monthsstandard authorization period
    3 monthsshortage authorization period

    Non-Preferred ESA Coverage Criteria

    Non-preferred product exception

    Coverage for a non-preferred product is provided when BOTH criteria are met.

    • Qualifying exception pathway

      • Inadequate response or treatment failure: The member has an inadequate response or treatment failure with all indicated and clinically appropriate preferred products.
      • Intolerable adverse event: The member experienced an intolerable adverse event with all preferred products, and, if applicable, the adverse event is not an expected adverse event attributed to the active ingredient, such as a known adverse reaction shared by reference and biosimilar products.
      • Contraindication: All preferred products are contraindicated for the member.
      • Shortage or unavailability: All preferred products are unavailable because of a drug shortage or other unavailability.
      • Preferential use supported by evidence or guidelines: Clinical evidence or current treatment guidelines support preferential use of the requested product over all preferred products.
      • Cancer treatment prerequisite-trial exception: The request is for cancer treatment in a state that prohibits prerequisite trials under applicable regulations.
    • Supporting clinical documentation: Clinical documentation is provided to support the exception request, including specific details of inadequate response or treatment failure, the nature and severity of adverse events, specific contraindications, the reasons all preferred products cannot be used, or notification of drug shortage or unavailability.

    The Plan does not cover non-preferred products when used for experimental, investigational, or medically unnecessary indications. This includes non-FDA-approved indications or off-label use without sufficient evidence of safety and efficacy; doses exceeding FDA-approved labeling or clinical practice guidelines without sufficient supporting evidence; uses not clinically appropriate based on indication, age, dosing, frequency, duration, site of administration, or contraindication; uses not required to treat or manage the member’s condition; uses not aligned with generally accepted medical practice; and uses primarily for convenience.

    Use is considered not medically necessary when it is not required for treatment or management of the member’s medical condition, is not aligned with generally accepted medical practice, or is primarily for the convenience of the member, family, or provider. Non-preferred products may also be considered not medically necessary when the indication, dose, frequency, duration, or administration site is not clinically appropriate.

    Initial Exception Authorization

    Initial non-preferred ESA exception

    A non-preferred ESA may be approved when the member meets BOTH the exception pathway and documentation requirements.

    • Exception pathway

      • Treatment failure or inadequate response: The member has treatment failure or an inadequate response to all clinically appropriate preferred products.
      • Intolerable adverse events: The member experienced intolerable adverse events with all preferred products, and, if applicable, the adverse events are not expected reactions attributable to an active ingredient shared by reference and biosimilar products.
      • Contraindication: All preferred products are contraindicated for the member.

    Continuation and Authorization Duration

    Continuation and authorization duration

    When the prior authorization criteria are met, authorization may continue for the applicable period.

    Authorization duration

    • Standard authorization: The requested product is authorized for up to 12 months.Up to 12 months
    • Drug shortage or unavailability: When approval is based on drug shortage or unavailability, initial approval is limited to up to 3 months and may be extended with continued documentation of the shortage or unavailability.Up to 3 months initially; extension possible with continued documentation

      If the shortage or unavailability resolves before the authorization period ends, the Plan may require transition to the preferred product at the next authorization period.

    Preferred ESA Step Therapy

    StepPreferred-product requirementException may apply when
    1Try all applicable preferred ESA products first when they are safe, effective, and clinically appropriate for the diagnosis.The member has inadequate response or treatment failure; an intolerable adverse event; a contraindication; shortage or unavailability of all preferred products; evidence or current treatment guidelines supporting preferential use of the requested product; or the request is for cancer treatment in a state that prohibits prerequisite trials.

    Authorization Period Limits

    Quantity limits
    Authorization periodUp to 12 months
    Quantity limits
    Initial approvalUp to 3 months
    ExtensionMay be extended based on continued documentation of shortage or unavailability

    Covered Billing Codes

    Covered HCPCS CodesHCPCSCovered
    J0881Injection, darbepoetin alfa, 1 microgram (non-ESRD use)
    J0882Injection, darbepoetin alfa, 1 microgram (for ESRD on dialysis)
    J0885Injection, epoetin alfa, (for non-ESRD use), 1000 units
    J0887Injection, epoetin beta, 1 microgram (for ESRD on dialysis)
    J0888Injection, epoetin beta, 1 microgram (for non-ESRD use)
    Q4081Injection, epoetin alfa, 100 units (for ESRD on dialysis)
    Q5105Injection, epoetin alfa-epbx, biosimilar (Retacrit) (for ESRD on dialysis), 100 units
    Q5106Injection, epoetin alfa-epbx, biosimilar (Retacrit) (for non-ESRD use), 1000 units

    Request Submission and Approval Requirements

    Prior Authorization

    Non-Preferred ESA Exception Authorization

    Prior authorization is required for requests for a non-preferred ESA. Coverage requires that the member meet both an exception pathway and the clinical-documentation requirement.

    • The member must meet one exception criterion: inadequate response or treatment failure, intolerable adverse event, contraindication, shortage or unavailability, evidence- or guideline-supported preferential use of the requested product, or a state-prohibited prerequisite trial for cancer treatment.
    • Clinical documentation supporting the applicable exception rationale must be submitted.
    Prior Authorization

    Submit Through the Correct Review Entity

    Route requests according to the indication. Oncology requests are reviewed by EviCore; non-oncology requests are submitted to Oscar through the applicable authorization channel.

    • Oncology: Submit through EviCore at www.evicore.com or call 855-252-1118.

    Erythropoiesis-Stimulating Agents

    Erythropoiesis-stimulating agents (ESAs) stimulate red blood cell production and are used for selected anemia-related indications. Covered uses may include anemia associated with chronic kidney disease, chemotherapy in patients with cancer, zidovudine treatment in patients with HIV infection, and certain other approved or evidence-supported uses, such as reducing transfusion requirements in elective noncardiac, nonvascular surgery and managing symptomatic anemia in lower-risk myelodysplastic syndromes. This policy addresses exceptions for obtaining a non-preferred physician-administered ESA when a preferred product cannot appropriately be used; it does not establish general ESA coverage.

    Key Policy Definitions

    Definitions
    DefinitionSummaries of drug information and medical evidence used to support decision-making about the appropriate use of drugs and medical procedures.
    ExamplesAmerican Hospital Formulary Service Drug Information; Elsevier Clinical Pharmacology; National Comprehensive Cancer Network Drugs and Biologics Compendium; Thomson Micromedex DrugDex; and United States Pharmacopeia-National Formulary (USP-NF).
    Definitions
    DefinitionA pre-existing condition or factor that precludes use of a drug due to risk of harm.
    Definitions
    DefinitionThe inability to tolerate or endure a medication or treatment because of subjectively difficult or harmful side effects, reactions, or hypersensitivities that negatively impact quality of life, ability to adhere, or overall health.

    Product Classification

    Billing Rule

    Bill Retacrit under the applicable HCPCS code

    Retacrit (epoetin alfa-epbx) is listed as a preferred product and appears in the billing table as an epoetin alfa biosimilar. Use the applicable HCPCS code based on the clinical setting and dialysis status.

    • Q5105: Injection, epoetin alfa-epbx, biosimilar (Retacrit), for ESRD on dialysis, 100 units.
    • Q5106: Injection, epoetin alfa-epbx, biosimilar (Retacrit), for non-ESRD use, 1000 units.
    Policy Summary
    PayerOscar Health
    PolicyErythropoiesis-Stimulating Agent (ESA) - Medical Benefit Preferred Physician-Administered Drug Exceptions Criteria
    Policy CodePolicy CG084
    Change TypeNo material change
    Effective DateApr 1, 2026
    Last ReviewDec 2, 2024
    Next Review DateN/A
    Key ActionSubmit prior authorization with clinical documentation supporting the non-preferred ESA exception.
    SourceLink
    On This Page
    Non-Preferred ESA Coverage CriteriaInitial Exception AuthorizationContinuation and Authorization DurationPreferred ESA Step TherapyAuthorization Period LimitsCovered Billing CodesRequest Submission and Approval RequirementsErythropoiesis-Stimulating AgentsKey Policy DefinitionsProduct Classification
    Shortage or unavailability: All preferred products are unavailable because of drug shortage or unavailability.
  1. Preferential use supported: Clinical evidence or current treatment guidelines support preferential use of the requested product over all preferred products.
  2. Cancer treatment exception: The request is for cancer treatment in a state that prohibits prerequisite trials under applicable regulations.
  3. Documentation: The provider submits clinical documentation supporting the applicable exception, such as details of treatment failure, adverse events, contraindications, reasons preferred products cannot be used, or drug shortage or unavailability.
  4. Non-oncology: Use the authorization tool at provider.hioscar.com, call 855-672-2755, or submit the form from www.hioscar.com/forms. The Plan also lists 800-540-2406 for authorization support.
  5. Step Therapy

    Complete Preferred-Product Step Therapy

    Use the Plan’s preferred ESA products first when they are safe, effective, indicated, and clinically appropriate. A non-preferred product requires documentation that the applicable preferred products cannot be used or that an exception applies.

    • Preferred products include Mircera, Procrit, and Retacrit.
    • Document trials of all indicated and clinically appropriate preferred products when required, including inadequate response, treatment failure, intolerance, or contraindication.
    • A preferred-product trial may be excepted for poor-response risk, clinical unsuitability, shortage or unavailability, evidence-supported preferential use of the requested product, or a state prohibition on prerequisite trials for cancer treatment.

    Unsupported block type: documentation<table>

    Documentation Required

    Submit Required Medical Records and Trial History

    Include records that establish the diagnosis, clinical appropriateness, prior treatment history, and any preferred-product trials or failures.

    • Up-to-date chart notes.
    • Relevant test results and imaging reports supporting the diagnosis.
    • Prescription claims records and/or prescription receipts documenting prior trials of alternatives.
    • Documentation of specific intolerable effects and their impact on treatment when intolerance is cited.
    Denial Risk

    Exception Criteria Must Be Met

    The request may be denied when the member does not meet at least one exception pathway, when all applicable preferred-product requirements are not addressed, or when supporting documentation is absent or inadequate.

    • Failure to document inadequate response, treatment failure, intolerance, contraindication, shortage or unavailability, evidence-supported preferential use, or an applicable state exception may result in denial.
    • Failure to provide clinical documentation supporting the stated exception may result in denial.
    • If the prior authorization criteria are met, authorization may be issued for up to 12 months.
    Denial Risk

    Avoid Non-Covered or Investigational Use

    Non-preferred ESAs are not covered when used for experimental, investigational, or medically unnecessary indications. The indication must be within FDA-approved labeling or supported by current medical evidence and standards of care.

    • Denial risk includes non-FDA-approved or unsupported off-label use, excessive dose or frequency, inappropriate duration or site of administration, or use inconsistent with accepted medical practice.
    • Do not request use that is not needed to treat or manage the member’s condition or that is primarily for the convenience of the member, family, or provider.
    • Consider age, dosing, duration, administration site, and contraindications when establishing clinical appropriateness.
    Denial Risk

    Preferred Therapy Must Be Tried or Justified as Unsuitable

    A non-preferred ESA may be denied when an applicable preferred product has not been tried first and no supported reason explains why the preferred therapy is unsuitable.

    • Document trial and failure or inadequate response to all FDA-, compendia-, or evidence-based guideline-supported preferred products that are indicated and clinically appropriate.
    • If preferred products were not tried, document the applicable contraindication, intolerance, poor-response risk, shortage or unavailability, evidence-supported preferential regimen, or state-mandated exception.
    • Preferred or formulary status does not eliminate the possibility of clinical prior authorization review.
    Definitions
    DefinitionWritten information used to support diagnoses and prior trials of alternatives.
    ExamplesUp-to-date chart notes, relevant test results, relevant imaging reports, prescription claims records, and prescription receipts.
    Definitions
    DefinitionProcedures, drugs, or devices that have not been proven effective or have not been approved by the appropriate regulatory bodies.
    Definitions
    DefinitionPlan requirements that must be met for a non-preferred drug to be approved for coverage.
    Example requirementTrial and failure of preferred drugs first.